Bela Ajtai, MD
Neurology · Amherst, NYNPI 1316155500
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,980 of the $164,899 with a category attached, or 77.6%. 38 manufacturers reported payments, led by Lilly USA, LLC at 59.3% of the total. Reporting peaked in 2024 at $99,111 and has fallen 67.9% since, to $31,827 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 641 payments — averaging $257.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$98K
- Eisai Inc.$31K
- Biogen$23K
- US Oncology Corporate, Inc.$2K
- Corium, LLC$2K
- Teva Pharmaceuticals USA, Inc.$2K
- plus $7K from 32 others
Across 40 payments — averaging $6227.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$178K
- Acadia Pharmaceuticals Inc$28K
- Avanir Pharmaceuticals, Inc.$22K
- Eisai Inc.$21K
Across 7 payments — averaging $48,459 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$339K
What the payments were for
- Consulting fees$10,2596%
- Speaking & faculty fees$127,98078%
- Travel & lodging$13,7108%
- Food & beverage$12,5428%
- Education$4080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 102 | $97,852 |
| Eisai Inc. | 64 | $31,425 |
| Biogen | 30 | $23,238 |
| US Oncology Corporate, Inc. | 5 | $1,752 |
| Corium, LLC | 6 | $1,723 |
| Teva Pharmaceuticals USA, Inc. | 74 | $1,557 |
| Avanir Pharmaceuticals, Inc. | 64 | $1,336 |
| AbbVie(2 entities) | 25 | $862 |
| Pfizer | 45 | $758 |
| Otsuka America Pharmaceutical, Inc. | 34 | $635 |
| Novartis | 20 | $428 |
| Kyowa Kirin, Inc. | 14 | $400 |
| Amgen | 19 | $397 |
| Acadia Pharmaceuticals Inc | 23 | $369 |
| Adamas Pharmaceuticals, Inc. | 14 | $300 |
| AstraZeneca(2 entities) | 15 | $277 |
| Neurocrine Biosciences, Inc. | 13 | $256 |
| Lundbeck LLC | 10 | $227 |
| UCB, Inc. | 6 | $191 |
| Alnylam Pharmaceuticals Inc. | 7 | $129 |
| Arbor Pharmaceuticals, Inc. | 4 | $110 |
| GE HealthCare | 10 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $84 |
| E.r. Squibb & Sons, L.L.C. | 5 | $81 |
| Tanabe Pharma America, Inc. | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 4 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $53 |
| GSK | 2 | $38 |
| Life Molecular Imaging Ltd | 2 | $35 |
| MDD US Operations, LLC | 2 | $31 |
| Boston Scientific | 1 | $30 |
| Abbott | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Bayer | 1 | $16 |
| Alkermes, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Sanofi | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,899 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $65,688 |
| Galantamine ErGalantamine Hbr | 558 | $51,114 |
| Memantine Hcl | 1,083 | $32,275 |
| RexultiBrexpiprazole | 15 | $26,098 |
| Memantine Hcl ErMemantine Hcl | 367 | $25,801 |
| Rivastigmine | 90 | $16,409 |
| Donepezil Hcl | 1,437 | $15,952 |
| Sertraline Hcl | 622 | $8,034 |
| Levetiracetam | 94 | $3,077 |
| Quetiapine Fumarate | 224 | $2,867 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 62 | $2,227 |
| Mirtazapine | 114 | $2,122 |
| Duloxetine Hcl | 52 | $1,819 |
| Ramelteon | 15 | $1,315 |
| Gabapentin | 54 | $1,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $635 | $26,09815 claims |
| Lilly USA, LLCOlanzapine | $97,852 | $56813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in Amherst
- Nicolas SaikaliAmherst$1.5M
- Jennifer McVigeAmherst$982K
- Bennett MyersAmherst$432K
- Laszlo MechtlerAmherst$347K
- Wisam ElmalikAmherst$289K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.